Prognostic Factors for Urachal Cancer: A Bayesian Model-Averaging Approach
Kim In-Kyong, 이주용, 권종규, 박재준, 조강수, 함원식, 홍성준, 양승철, 최영득,
소속 상세정보
( Kim In-Kyong )
Yonsei University College of Medicine Severance Hospital Department of Urology
이주용 ( Lee Joo-Yong )
Yonsei University College of Medicine Severance Hospital Department of Urology
권종규 ( Kwon Jong-Kyou )
Yonsei University College of Medicine Severance Hospital Department of Urology
박재준 ( Park Jae-Joon )
Yonsei University College of Medicine Severance Hospital Department of Urology
조강수 ( Cho Kang-Su )
Yonsei University College of Medicine Gangnam Severance Hospital Department of Urology
함원식 ( Ham Won-Sik )
Yonsei University College of Medicine Severance Hospital Department of Urology
홍성준 ( Hong Sung-Joon )
Yonsei University College of Medicine Severance Hospital Department of Urology
양승철 ( Yang Seung-Choul )
Yonsei University College of Medicine Severance Hospital Department of Urology
최영득 ( Choi Young-Deuk )
Yonsei University College of Medicine Severance Hospital Department of Urology
KMID : 0358320140550090574
Abstract
Purpose: This study was conducted to evaluate prognostic factors and cancer-specific survival (CSS) in a cohort of 41 patients with urachal carcinoma by use of a Bayesian model-averaging approach.
Materials and Methods: Our cohort included 41 patients with urachal carcinoma who underwent extended partial cystectomy, total cystectomy, transurethral resection, chemotherapy, or radiotherapy at a single institute. All patients were classified by both the Sheldon and the Mayo staging systems according to histopathologic reports and preoperative radiologic findings. Kaplan-Meier survival curves and Cox proportional-hazards regression models were carried out to investigate prognostic factors, and a Bayesian model-averaging approach was performed to confirm the significance of each variable by using posterior probabilities.
Results: The mean age of the patients was 49.88±13.80 years and the male-to-female ratio was 24:17. The median follow-up was 5.42 years (interquartile range, 2.8-8.4 years). Five- and 10-year CSS rates were 55.9% and 43.4%, respectively. Lower Sheldon (p=0.004) and Mayo (p<0.001) stage, mucinous adenocarcinoma (p=0.005), and larger tumor size (p=0.023) were significant predictors of high survival probability on the basis of a log-rank test. By use of the Bayesian model-averaging approach, higher Mayo stage and larger tumor size were significant predictors of cancer-specific mortality in urachal carcinoma.
Conclusions: The Mayo staging system might be more effective than the Sheldon staging system. In addition, the multivariate analyses suggested that tumor size may be a prognostic factor for urachal carcinoma.
키워드
Follow-up studies;Survival;Urachal cancer
원문 및 링크아웃 정보
등재저널 정보